vs
Side-by-side financial comparison of FIRST COMMONWEALTH FINANCIAL CORP (FCF) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
FIRST COMMONWEALTH FINANCIAL CORP is the larger business by last-quarter revenue ($133.7M vs $129.7M, roughly 1.0× Travere Therapeutics, Inc.). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs 13.0%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs 5.5%).
First Commonwealth Financial Corp is a Pennsylvania-based regional financial services holding company. It offers consumer and commercial banking products, loans, wealth management, and insurance services for individuals, small and mid-sized enterprises across central and western Pennsylvania and Ohio.
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
FCF vs TVTX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $133.7M | $129.7M |
| Net Profit | $37.5M | — |
| Gross Margin | — | 98.0% |
| Operating Margin | — | -25.0% |
| Net Margin | 28.1% | — |
| Revenue YoY | 13.0% | 73.4% |
| Net Profit YoY | -16.3% | — |
| EPS (diluted) | $0.37 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $133.7M | — | ||
| Q4 25 | $137.9M | $129.7M | ||
| Q3 25 | $136.0M | $164.9M | ||
| Q2 25 | $131.0M | $114.4M | ||
| Q1 25 | $118.0M | $81.7M | ||
| Q4 24 | $120.4M | $74.8M | ||
| Q3 24 | $121.2M | $62.9M | ||
| Q2 24 | $120.2M | $54.1M |
| Q1 26 | $37.5M | — | ||
| Q4 25 | $44.9M | — | ||
| Q3 25 | $41.3M | $25.7M | ||
| Q2 25 | $33.4M | $-12.8M | ||
| Q1 25 | $32.7M | $-41.2M | ||
| Q4 24 | $35.8M | — | ||
| Q3 24 | $32.1M | $-54.8M | ||
| Q2 24 | $37.1M | $-70.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | 98.0% | ||
| Q3 25 | — | 99.0% | ||
| Q2 25 | — | 98.7% | ||
| Q1 25 | — | 94.3% | ||
| Q4 24 | — | 96.6% | ||
| Q3 24 | — | 97.4% | ||
| Q2 24 | — | 96.2% |
| Q1 26 | — | — | ||
| Q4 25 | 40.9% | -25.0% | ||
| Q3 25 | 38.1% | 15.1% | ||
| Q2 25 | 32.1% | -11.1% | ||
| Q1 25 | 34.8% | -52.2% | ||
| Q4 24 | 37.1% | -81.2% | ||
| Q3 24 | 33.4% | -89.3% | ||
| Q2 24 | 38.7% | -125.1% |
| Q1 26 | 28.1% | — | ||
| Q4 25 | 32.5% | — | ||
| Q3 25 | 30.4% | 15.6% | ||
| Q2 25 | 25.5% | -11.1% | ||
| Q1 25 | 27.7% | -50.4% | ||
| Q4 24 | 29.8% | — | ||
| Q3 24 | 26.5% | -87.1% | ||
| Q2 24 | 30.9% | -130.1% |
| Q1 26 | $0.37 | — | ||
| Q4 25 | $0.44 | $0.04 | ||
| Q3 25 | $0.39 | $0.28 | ||
| Q2 25 | $0.32 | $-0.14 | ||
| Q1 25 | $0.32 | $-0.47 | ||
| Q4 24 | $0.35 | $-0.71 | ||
| Q3 24 | $0.31 | $-0.70 | ||
| Q2 24 | $0.36 | $-0.91 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $93.0M |
| Total DebtLower is stronger | $154.9M | — |
| Stockholders' EquityBook value | $1.6B | $114.8M |
| Total Assets | $12.3B | $605.2M |
| Debt / EquityLower = less leverage | 0.10× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $93.0M | ||
| Q3 25 | — | $110.9M | ||
| Q2 25 | — | $75.2M | ||
| Q1 25 | — | $61.9M | ||
| Q4 24 | — | $58.5M | ||
| Q3 24 | — | $36.4M | ||
| Q2 24 | — | $32.3M |
| Q1 26 | $154.9M | — | ||
| Q4 25 | $261.7M | — | ||
| Q3 25 | $262.1M | — | ||
| Q2 25 | $262.4M | — | ||
| Q1 25 | $262.7M | — | ||
| Q4 24 | $263.0M | — | ||
| Q3 24 | $136.3M | — | ||
| Q2 24 | $136.6M | — |
| Q1 26 | $1.6B | — | ||
| Q4 25 | $1.6B | $114.8M | ||
| Q3 25 | $1.5B | $73.6M | ||
| Q2 25 | $1.5B | $32.7M | ||
| Q1 25 | $1.4B | $32.8M | ||
| Q4 24 | $1.4B | $59.1M | ||
| Q3 24 | $1.4B | $-30.5M | ||
| Q2 24 | $1.4B | $15.1M |
| Q1 26 | $12.3B | — | ||
| Q4 25 | $12.3B | $605.2M | ||
| Q3 25 | $12.3B | $538.6M | ||
| Q2 25 | $12.2B | $555.3M | ||
| Q1 25 | $11.8B | $548.8M | ||
| Q4 24 | $11.6B | $594.1M | ||
| Q3 24 | $12.0B | $504.4M | ||
| Q2 24 | $11.6B | $551.1M |
| Q1 26 | 0.10× | — | ||
| Q4 25 | 0.17× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | 0.17× | — | ||
| Q1 25 | 0.18× | — | ||
| Q4 24 | 0.19× | — | ||
| Q3 24 | 0.10× | — | ||
| Q2 24 | 0.10× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $60.7M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $187.5M | $60.7M | ||
| Q3 25 | $49.5M | $14.3M | ||
| Q2 25 | $30.4M | $5.0M | ||
| Q1 25 | $55.9M | $-42.2M | ||
| Q4 24 | $129.5M | $-35.7M | ||
| Q3 24 | $53.6M | $-42.5M | ||
| Q2 24 | $22.7M | $-40.2M |
| Q1 26 | — | — | ||
| Q4 25 | $171.5M | — | ||
| Q3 25 | — | $14.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $113.9M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-40.3M |
| Q1 26 | — | — | ||
| Q4 25 | 124.3% | — | ||
| Q3 25 | — | 8.6% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 94.6% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -74.5% |
| Q1 26 | — | — | ||
| Q4 25 | 11.7% | — | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 12.9% | — | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.2% |
| Q1 26 | — | — | ||
| Q4 25 | 4.18× | — | ||
| Q3 25 | 1.20× | 0.56× | ||
| Q2 25 | 0.91× | — | ||
| Q1 25 | 1.71× | — | ||
| Q4 24 | 3.61× | — | ||
| Q3 24 | 1.67× | — | ||
| Q2 24 | 0.61× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FCF
Segment breakdown not available.
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
